Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of one randomized controlled trial(s). ^[1]
• Rifamycin-SV significantly reduced Time to Last Unformed Stool (TLUS) compared to placebo in all severity groups, with a Hazard Ratio (HR) of 1.9 (P = 0.0006) for all subjects, 5.9 (P = 0.0232) in severe cases, and 1.7 (P = 0.0078) in moderate cases.
• Rifamycin-SV was equally efficacious compared to ciprofloxacin, with HR 0.962 (P = NS) for all subjects, HR 0.9 (P = NS) in moderate cases, and HR 1.2 (P = NS) in severe cases.
• TLUS was longer in severe cases (HR 0.24; P < 0.001; n = 173) compared to moderate (HR 0.54; P = 0.0272; n = 912) and mild cases, but rifamycin-SV showed consistent effectiveness across all severity groups.
• There is no safety information available in the reviewed studies.
• A total of 1098 participants from two double-blind Phase 3 trials were analyzed, categorized into mild, moderate, and severe Traveler's Diarrhea (TD) based on signs, symptoms, and number of loose stools, with the severity classification demonstrating strong prognostic value for holistic assessment and consistent effectiveness of rifamycin-SV across all severity levels.